$17,000 of BIOREFERENCE LABORATORIES AN OPKO HEALTH COMPANY lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Concerns on patient impact of FDA LDT regulation Clinical laboratory payment issues under PAMA"
You can find more data on corporate lobbying on Quiver Quantitative.
OPK Insider Trading Activity
OPK insiders have traded $OPK stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $OPK stock by insiders over the last 6 months:
- PHILLIP MD ET AL FROST (CEO & Chairman) has traded it 6 times. They made 6 purchases, buying 1,304,255 shares and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
OPK Hedge Fund Activity
We have seen 83 institutional investors add shares of OPK stock to their portfolio, and 91 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RUBRIC CAPITAL MANAGEMENT LP added 4,284,336 shares (+9.6%) to their portfolio in Q3 2024
- CITADEL ADVISORS LLC added 2,157,341 shares (+626.5%) to their portfolio in Q3 2024
- PORTOLAN CAPITAL MANAGEMENT, LLC removed 1,886,749 shares (-100.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 1,214,946 shares (+96.3%) to their portfolio in Q3 2024
- VANGUARD GROUP INC added 976,017 shares (+3.5%) to their portfolio in Q3 2024
- VOYA INVESTMENT MANAGEMENT LLC removed 929,087 shares (-31.0%) from their portfolio in Q3 2024
- ASSENAGON ASSET MANAGEMENT S.A. added 876,272 shares (+142.5%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
